Success Metrics

Clinical Success Rate

100.0%

Based on 4 completed trials

Completion Rate

100%(4/4)

Active Trials

0(0%)

Results Posted

100%(4 trials)

Phase Distribution

Ph not_applicable

17%

Ph phase_2

33%

Ph phase_1

17%

Ph phase_4

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution6 total trials

Phase 1Safety & dosage

1(16.7%)

Phase 2Efficacy & side effects

2(33.3%)

Phase 4Post-market surveillance

2(33.3%)

N/ANon-phased studies

1(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(4)

Terminated(2)

Detailed Status

Completed4

Withdrawn2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Phase 11 (16.7%)

Phase 22 (33.3%)

Phase 42 (33.3%)

N/A1 (16.7%)

Trials by Status

completed467%

withdrawn233%

Recent Activity

0 active trials

Showing 5 of 6

completedphase_4

Clinical Trials (6)

Showing 6 of 6 trials

NCT02859142Phase 4

Varenicline Augmentation of Patch Outcomes in Heavy Drinkers' Smoking Cessation

Completed

NCT02360631Phase 4

Advancing Tobacco Use Treatment for African American Smokers

Completed

NCT03069768Phase 1

Stage Ib Trial of mSMART With Varenicline

Withdrawn

NCT00895557Phase 2

Assessing the Impact of Varenicline on Brain-Behavior Vulnerability

Withdrawn

NCT01806779Phase 2

Combination Bupropion / Varenicline for Smoking Cessation in Male Smokers

Completed

NCT00781599Not Applicable

Improving Medication Compliance and Smoking Cessation Treatment Outcomes for African American Smokers

Completed

All 6 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 6